Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance ...

On December 17, 2024, the Competition Tribunal (the Tribunal) issued reasons for its decision to dismiss an application for leave to bring a ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of these two cytokines on T cells, natural killer cells, and antigen-presenting cells.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...

After hours: January 28 at 5:45:53 PM EST Loading Chart for RANI ...

Vedolizumab prevented the postoperative recurrence of Crohn’s disease and should be considered a prophylactic treatment in patients with at least one risk factor for recurrence.

051900.KS LG H&H Co., Ltd.

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...